A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

We should not lose sight of how wonderfully productive the biomedical research enterprise — now under threat — can be. The ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

Amazon retail en mutation, duel Novo Nordisk/Lilly, percée de la suzetrigine… Le point sur les grandes tendances santé et ...

The following is a summary of “Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the ...

Medscape News Slideshows, January 31, 2025 Alert FDA OKs First-In-Class Nonopioid Pain Med Suzetrigine Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous ...